The University of Tokyo

Nanocarrier Co., Ltd.

Other

Nippon Kayaku Kabushiki Kaisha

Tokyo Institute of Technology

Japan Science and Technology Corporation

Kawasaki Institute of Industrial Promotion

Japan Science and Technology Agency

Sakurai, Yasuhisa

Yasuhisa Sakurai

Kazuhisa Shimizu

Tomoko Akutsu

Megumi Machida

Shigeto Fukushima

Takeshi Nakanishi

Kazunori Kataoka

Nobuhiro Nishiyama

Kanjiro Miyata

Yasuki Kato

Keiji Itaka

Kensuke Osada

Sumiyo Watanabe

Naoki Kanayama

Atsushi Harada

Hiroyasu Takemoto

Hiroyuki Chaya

Kazuya Okamoto

Masayuki Yokoyama

Masataka Nakanishi

Takahiro Nomoto

Yutaka Miura

Horacio Cabral

HyunJin Kim

Masanobu Suzuki

Yu Matsumoto

Yuichi Yamasaki

Ryuji Uehara

Kotaro Hayashi

Hiroko Mashiba

Hiroaki Kinoh

Kazuko Toh

Aya Koide

Joon-Sik Park

Tsukasa Chida

Ronald James Christie

Woo-Dong Jang

Shunsaku Asano

Kensuke The University Of Tokyo Osada

Kazunori The University Of Tokyo Kataoka

Joon-Sik The University Of Tokyo Park

Yuichi The University Of Tokyo Yamasaki

Naoki Bamboo-House 203 Kanayama

Atsushi Gransifort-Nakamozu 3-1413 Harada

A unit-type polyion complex for use in delivering nucleic acid to a target site in a patient includes one or more molecules of a block copolymer having a poly(ethylene glycol) segment and a cationic poly(amino acid) segment and one or more molecules of a nucleic acid. A total quantity of positive charges derived from side chains of the cationic poly(amino acid) segment of the block copolymer in the unit-type polyion complex is not offset by a total quantity of negative charges derived from the nucleic acid. Furthermore, the nucleic acid has a strand length of 10-50 bases, the molecular weight of the poly(ethylene glycol) segment is 40&#xd7;10or more, and the block copolymer has a binding constant (Ka) for the nucleic acid of 3.0&#xd7;10or more.

Nucleic acid-loaded unit polyion complex

A unit structure-type pharmaceutical composition includes a single nucleic acid, such as an antisense nucleic acid, electrostatically bound to a single block copolymer having a cationic polyamino acid segment and a hydrophilic polymer chain segment. The negative charges of the nucleic acid are counterbalanced, at least substantially, by the positive charges of the cationic polyamino acid segment such that the pharmaceutical composition is electrically neutral or nearly electrically neutral. Further, the nucleic acid is covered with the hydrophilic polymer chain segment. The block copolymer thereby improves the blood retention capability of the nucleic acids.

Unit structure-type pharmaceutical composition for nucleic acid delivery

The problem addressed by the present invention is to develop a pharmaceutical having therapeutic efficacy against epirubicin-resistant tumors. The present invention provides a micelle having an anti-cancer agent disposed inside the core of the micelle formed by an epirubicin-conjugated copolymer.

Micelle containing epirubicin-complexed block copolymer and anti-cancer agent, and pharmaceutical composition containing said micelle applicable to treatment of cancer, resistant cancer or metastatic cancer

A unit structure-type pharmaceutical composition includes at least one nucleic acid, such as siRNA, electrostatically bound to at least one block copolymer having a cationic polyamino acid segment and a hydrophilic polymer chain segment. The negative charge(s) of the nucleic acid are counterbalanced, at least substantially, by the positive charge(s) of the cationic polyamino acid segment such that the pharmaceutical composition is electrically neutral or nearly electrically neutral. Further, the nucleic acid is covered with the hydrophilic polymer chain segment(s). The at least one block copolymer thereby improves the blood retention capability of the nucleic acid(s).

A composition of matter for use in encapsulating a drug is expressed by formula (1) or formula (2): wherein Rand Rare each independently a hydrogen atom or a substituted or unsubstituted, linear or branched alkyl group having 1 to 12 carbon atoms; A is a hydrophilic polymer chain; Land Lare each a linking group; B is a cation-containing group; Ris a side chain of an amino acid; z is an integer of 5 to 500; x is an integer of 40% or more of z; y is 0 or a positive integer; z-x-y is 0 or a positive integer; p is an integer of 1 to 10; and q is an integer of 1 to 10.

Particle composition and pharmaceutical composition using particle composition

The invention provides block copolymers formed of poly(ethylene glycol) segments and poly(amino acid derivative) segments having side chains of at least one kind of specific amine residue. The invention also provides polyion complexes of such copolymers with polynucleotides and the like. These block copolymers are useful as carriers for in vivo delivery of active substances such as DNA.

Polyethylene glycol/polycation block copolymers

The present invention discloses a vesicle which is excellent in structure stability and environmental responsiveness and also can be produced by a simple operation. More particularly, the present invention discloses a vesicle comprising a membrane formed of a first block copolymer containing a non-chargeable hydrophilic segment and a chargeable segment, and a second block copolymer containing a non-chargeable hydrophilic segment and a chargeable segment having an electric charge which is opposite to that of the chargeable segment of the first block copolymer.

Electrostatically bonded polymer vesicle

Disclosed is a composition for the delivery of nucleic acid to target cells or tissues, which comprises a polycationically charged polymer as a carrier of nucleic acid. The polycationically charged polymer is a polymer which may comprise a charged polymer segment having a main chain based on poly(amino acid), polysaccharide, polyester, polyether, polyurethane or vinyl polymer and having, as a side chain, a group of formula &#x2014;NH&#x2014;(CH)&#x2014;(NH(CH))&#x2014;NH(wherein a and e independently denote an integer of 1 to 5) which is connected to the main chain either directly or via a linker. The disclosed composition has low toxicity, and has a high efficiency in introducing nucleic acid into cells.

Polycationically charged polymer and the use of the same as a carrier for nucleic acid

Anthracycline compound derivative and pharmaceutical preparation

Growing community of inventors

Tokyo, Japan

Shigeto Fukushima